Topics

 Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial

12:00 EDT 8 Apr 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
PXL065 observed to have a favorable safety, tolerability and pharmacokinetic profile in the Phase 1a trial PXL065 is advancing into a Phase 1b multiple ascending dose trial to support a pivotal Phase ...

Other Sources for this Article

Poxel SA
Jonae R. Barnes
Senior Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
+1 (617) 818-2985

Investor relations / Media - EU/US
Trophic Communications
Stephanie May or Joanne Tudorica
may@trophic.eu
+49 89 238 877 34 or +49 171 185 56 82

Investor relations / Media - France
NewCap
Alexia Faure/Nicolas Merigeau
poxel@newcap.eu
+33 1 44 71 94 94

NEXT ARTICLE

More From BioPortfolio on " Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial"

Quick Search